低價(jià)供應(yīng) PA-1 人卵巢畸胎瘤細(xì)胞 CRL-1572 PA-1 人卵巢畸胎瘤細(xì)胞，ATCC 細(xì)胞|細(xì)胞系|細(xì)胞株|腫瘤細(xì)胞|細(xì)胞|貼壁細(xì)胞|懸浮細(xì)胞|,細(xì)胞庫(kù)管理規(guī)范,提供的細(xì)胞株背景清楚,提供參考文獻(xiàn)和*培養(yǎng)條件
低價(jià)供應(yīng) PA-1 人卵巢畸胎瘤細(xì)胞，ATCC 細(xì)胞|細(xì)胞系|細(xì)胞株|腫瘤細(xì)胞|細(xì)胞|貼壁細(xì)胞|懸浮細(xì)胞|,細(xì)胞庫(kù)管理規(guī)范,提供的細(xì)胞株背景清楚,提供參考文獻(xiàn)和*培養(yǎng)條件
CRL-1572 PA-1 人卵巢畸胎瘤細(xì)胞 的詳細(xì)介紹
CRL-1572 PA-1 人卵巢畸胎瘤細(xì)胞
| ATCC® Number: | CRL-1572™ | 低價(jià)供應(yīng) PA-1 人卵巢畸胎瘤細(xì)胞 | |
| Designations: | PA-1 | | Depositors: | BC Giovanella | | Biosafety Level: | 1 | | Shipped: | frozen | | Medium & Serum: | See Propagation | | Growth Properties: | adherent | | Organism: | Homo sapiens （human） | | Morphology: | epithelial
| | Source: | Organ: ovary
Disease: teratocarcinoma
Derived from metastatic site: ascites | | Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | | | | Tumorigenic: | Yes | | Oncogene: | N-ras + （activated） | | Antigen Expression: | HLA A28, B12 | | DNA Profile （STR）: | Amelogenin: X
CSF1PO: 9,12
D13S317: 9,10
D16S539: 9,12
D5S818: 11
D7S820: 9
THO1: 7,9
TPOX: 11
vWA: 15,17 | | Isoenzymes: | G6PD, B | | Age: | 12 years | | Gender: | female | | Ethnicity: | Caucasian | | Comments: | The line was established from cells taken from ascitic fluid.
The cells form tightly knit colonies, and differentiate to form embryoid bodies when cultured in low serum concentration, or at low plating densities or when treated with 5-bromo-2'-deoxyuridine.
The embryonic antigen PCC4 is expressed, but F9 is not detectable. | | Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: heat-inactivated fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C | | Subculturing: | Subc*tion Ratio: A subc*tion ratio of 1:4 to 1:10 is recommended
Medium Renewal: 2 to 3 times per week
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature （or at 37C） until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks. | | Preservation: | culture medium 95%; DMSO, 5% | | Related Products: | Recommended medium （without the additional supplements or serum described under ATCC Medium）:ATCC 30-2003 | | References: | 22179: . . In Vitro 10: 382, 1974.
22368: Zeuthen J, et al. Characterization of a human ovarian teratocarcinoma-derived cell line. Int. J. Cancer 25: 19-32, 1980. PubMed: 6931103
22530: Giovanella BC, et al. Heterotransplantation of human malignant tumors in "nude" thymusless mice. II. Malignant tumors induced by injection of cell cultures derived from human solid tumors. J. Natl. Cancer Inst. 52: 921-930, 1974. PubMed: 4524119
22950: Tainsky MA, et al. An activated rasN gene: detected in late but not early passage human PA1 teratocarcinoma cells. Science 225: 643-645, 1984. PubMed: 6740333
23112: McGowan-Jordan IJ, et al. Suppression of tumorigenicity in human teratocarcinoma cell line PA-1 by introduction of chromosome 4. Cancer Res. 54: 2568-2572, 1994. PubMed: 8168081 |
|
會(huì)員.png)
15
